13.99 0.00 (0.00%)
After hours: 4:00PM EDT
Thanks to bad news for its competitor, this company behind the first FDA-approved peanut allergy treatment could be ripe for a rebound.
Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Before we begin, I would like to remind you that during today's call and Q&A session, we will be making forward-looking statements. Risks and uncertainties that contribute to the uncertain nature of these forward-looking statements include the effects of the COVID-19 pandemic on our business and financial condition; the expectation that Aimmune will need additional funds to finance its operations; Aimmune's dependence on the success of PALFORZIA; Aimmune's ability to build a commercial field organization and distribution network; the degree of acceptance of PALFORZIA among physicians, patients, healthcare payers, patient advocacy groups and the general medical community; Aimmune's ability to obtain favorable coverage and reimbursement from third-party payers for PALFORZIA; Aimmune's ability to implement and comply with the REMS for PALFORZIA; Aimmune's or any of its collaborative partners' ability to initiate and/or complete clinical trials; the unpredictability of the regulatory process; the possibility that Aimmune's or any of its collaborative partners' clinical trials will not be successful; the reliance on third parties for the manufacture of PALFORZIA and our product candidates; possible regulatory developments in the United States and foreign countries; and Aimmune's ability to attract and retain senior management personnel.